Eprenetapopt

Eprenetapopt

SCHEMBL21636035

COCC1(CO)C(=O)[C@H]2CC[N@@]1CC2

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TP53

The experimentally established mechanism targets of Eprenetapopt. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.72
MAPT P10636 1/20 0.72
CYP2C9 P11712 1/20 0.72
CYP2C19 P33261 1/20 0.72
KMT2A Q03164 1/20 0.72
MMP3 P08254 1/20 0.30
MMP8 P22894 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eprenetapopt SCHEMBL23726645 1.00 MEN1 (0.72) MEN1MAPTCYP2C9CYP2C19KMT2A
Eprenetapopt SCHEMBL27272034 1.00 MEN1 (0.72) MEN1MAPTCYP2C9CYP2C19KMT2A
Eprenetapopt SCHEMBL2228161 1.00 MEN1 (0.72) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL29965401 0.94 MEN1 (0.64) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL29965910 0.94 MEN1 (0.64) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL29965601 0.94 MEN1 (0.64) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL29965376 0.94 MEN1 (0.64) MEN1MAPTCYP2C9CYP2C19KMT2A
Eprenetapopt SCHEMBL28990156 0.92 MEN1 (0.60) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL30382084 0.91 MEN1 (0.58) MEN1MAPTCYP2C9CYP2C19KMT2A
SCHEMBL23727096 0.91 MEN1 (0.58) MEN1MAPTCYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020016155-A1 METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING IN A SUBJECT SUFFERING FROM ECTODERMAL DYSPLASIAS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-01-23 WO disclosed